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ABSTRACT
We have developed a self-inactivating PiggyBac
transposon system for tamoxifen inducible
insertional mutagenesis from a stably integrated
chromosomal donor. This system, which we have
named ‘Slingshot’, utilizes a transposon carrying
elements for both gain- and loss-of-function
screens in vitro. We show that the Slingshot trans-
poson can be efficiently mobilized from a range
of chromosomal loci with high inducibility and low
background generating insertions that are randomly
dispersed throughout the genome. Furthermore, we
show that once the Slingshot transposon has been
mobilized it is not remobilized producing stable
clonal integrants in all daughter cells. To illustrate
the efficacy of Slingshot as a screening tool we set
out to identify mediators of resistance to puromycin
and the chemotherapeutic drug vincristine by per-
forming genetrap screens in mouse embryonic stem
cells. From these genome-wide screens we
identified multiple independent insertions in the
multidrug resistance transporter genes Abcb1a/b
and Abcg2 conferring resistance to drug treatment.
Importantly, we also show that the Slingshot trans-
poson system is functional in other mammalian cell
lines such as human HEK293, OVCAR-3 and PE01
cells suggesting that it may be used in a range of
cell culture systems. Slingshot represents a flexible
and potent system for genome-wide transposon-
mediated mutagenesis with many potential
applications.
INTRODUCTION
The complexity of the genes, pathways and networks that
dictate many cellular phenotypes rarely makes it possible
to employ a candidate gene (reverse genetic) approach
to identify potential mediators of a biological process.
In contrast genome-wide forward genetic screens, which
may be performed without making a priori assumptions
about the candidature of individual genes in a process,
represent a powerful approach for gene discovery.
Classically forward genetic screens in higher order organ-
isms have been performed using ionizing radiation,
chemical mutagens, or viruses each of which are likely
to target a different repertoire of genes. While these
approaches can be extremely efﬁcient at generating
mutants with a phenotype of interest the subsequent iden-
tiﬁcation of causal mutations is often cumbersome.
This is particularly the case for traditional chemical
mutagens such as N-ethyl-N-nitrosourea (ENU) and
ethyl-methanesulfonate, which generate genome-wide
point mutations and in so doing signiﬁcant background
noise from which a candidate gene carrying a mutation
must be identiﬁed and then validated (1,2). Similarly,
while ionizing radiation is a powerful tool for mutagenesis
generating sufﬁciently small chromosomal rearrangements
so that a candidate gene can be identiﬁed using
approaches such as comparative genomic hybridization
requires high doses of radiation to be used which generates
a signiﬁcant number of rearrangements, the majority
of which represent background (3). Lower doses pro-
duce rearrangements of large chromosomal regions, in
some cases containing hundreds of genes, complicating
follow-up analysis (3). Even viruses, which can be
introduced as single copy integrants into the genome,
may function many megabases distal to their integration
site (4). Viruses also exhibit strong insertional biases
preferring to insert into active promoters and into open
chromatin, which effectively reduces the compendium of
genes that they can mutate (5).
Transposons are mobile genetic elements that constitute
a major part of the repetitive sequence of eukaryotic
genomes (6). Transposons may be classiﬁed into
two groups; DNA transposons and retrotransposons.
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a transposable element, which allows them to be mobilized
and relocated to other locations in the genome by a
‘cut-and-paste’ mechanism. Retrotransposons function
by a ‘copy-and-paste’ mechanism (7). In lower organisms
(worms, bacteria, Drosophila), DNA transposons have
been used extensively for genetic manipulation and for
mutagenesis (8–10). In recent years, DNA transposons
have also been used for insertional mutagenesis screens
in vertebrates. In zebraﬁsh Tol2 has gained popularity,
but has limited activity in mammalian cells and in vivo
(11). Other transposons including Minos have also been
trialled in mammalian cells but with mixed success (12). In
contrast the Tc1-family transposon Sleeping Beauty (SB)
has been shown to be effective for cancer gene discovery
screens in vivo (13,14), and is an active mutagen in the
germline (15–17). While SB is active in some cell lines
such as 293T and HeLa cells, is appears to be weakly
active in embryonic stem (ES) cells (18). SB also exhibits
signiﬁcant ‘local hopping’, a phenomenon where a
mobilized transposon re-integrates close to the donor
locus (15,17,18), and to have a limited cargo capacity
with mobilization being signiﬁcantly reduced when
elements of >3kb are cloned between the inverted
repeats/direct repeats (IR/DR) of the transposon (19).
These factors, coupled with overexpression inhibition
where optimal transposition is obtainable within a
narrow window of transposase expression, and is
repressed at high levels of expression, limits the utility of
SB as a universal mutagen. Despite these factors
SB-mediated screens have been successfully performed in
cell culture systems (20). More recently considerable effort
has been invested in developing the transposon PiggyBac
(PB) from the moth Trichoplusia ni, as a tool for
insertional mutagenesis (21–26). Mobilization of PB
from donor loci results in a more random distribution of
transposon insertion events around the genome than is
obtainable with SB or Tol2. PB can mobilize large cargo
containing transposons (as big as several hundred kilo-
bases) and unlike SB expression of the PB transposase at
high levels does not appear to result in overexpression
inhibition (24). Another advantage of PB is that the PB
transposase is still active when fused with other proteins
such as the oestrogen receptor ligand-binding domain
(ERT2) opening up a range of possibilities for temporally
controlled mutagenesis (25). In addition to these factors
PB appears to be highly active in mammalian cells
generating multiple independent insertions in cells into
which the transposon is introduced. Collectively these
factors suggest that PB is a powerful mutagen complemen-
tary to other tools. In particular PB may be used in
combination with loss of the Bloom syndrome helicase
for recessive screens (23,27).
The most common method for introducing PB, or
indeed other transposons, into mammalian cells is to
co-transfect a plasmids expressing the transposase
(‘helper’ plasmid) and another plasmid carrying a trans-
poson (‘donor’ plasmid) (28). Once transfected into the
host cells the transposase enzyme mobilizes the trans-
poson from the donor plasmid and integrates it into the
host genome. The number of transposon integration
events can be controlled to some extent by titering the
amount of plasmid and the ratio of the helper and
donor plasmids but integration patterns are frequently
complex (23). Similarly, once integrated continued expres-
sion of the transposase can re-mobilize transposon inte-
gration events generating a complex pattern of
integrations in subsequent cell divisions. To overcome
these limitations we have developed a novel PB system
for self-inactivating insertional mutagenesis, which we
have named Slingshot. The name Slingshot refers to a
single shot handheld weapon. Here we show that this
system can be used for ligand inducible insertional muta-
genesis using 4-Hydroxytamoxifen (4-OHT) generating
single stable integration events distributed genome-wide.
Transposition and trapping efﬁciency is extremely high
such that as many as 30000 clonal insertion events can
be generated from a single 10-cm plate of cells making it
feasible to screen all permissive genes and regions of the
genome in just a few plates of cells in culture.
MATERIALS AND METHODS
Plasmids construction
The PB Slingshot transposon with 50 and 30 PB terminal
repeats ﬂanking a splice acceptor-IRES, promoterless
 -geo, and a cytomegalovirus early enhancer/chicken
b-actin (CAG) (CAGGS) promoter was constructed
using elements derived from the plasmids 50-PTK-30,
pGTo1xr and pcDNA3.1 (25). The PB transposase
estrogen receptor fusion (mPB-L3-ERT2) cDNA was
obtained from Cadinanos and Bradley (25). The ﬁnal
Slingshot plasmid (Figure 1) was constructed with a
pBluescript II SK(+) vector backbone using standard
approaches and was sequenced in full. The vector has
accession number GU937109.
Cell culture and transfection
To generate stable integrants carrying the Slingshot
plasmid ES cell were electroporated with 40mgo fPacI
linearized Slingshot plasmid DNA; 10
7 E14Tg2a ES cells
at 230V, 500mF using a BIO-RAD Gene Pulser II
Electroporator. Cells were cultured on a 10-cm culture
dish after transfection and selected with 15mg/ml
blasticidin (BSD) for 10days. Individual clones were
picked into 96-well plates for downstream analysis. All
other cell lines were cultured in DMEM.
Trapping efﬁciency test
The trapping efﬁciency of slingshot integrated ES cells was
evaluated by plating cell lines in duplicate into adjacent
wells of a six-well plate and treating one well with 1mM
4-OHT for 2 days, and the other well with 95% ethanol
vehicle as a control. Cells were then cultured under G418
selection (175mg/ml) for 8days to select for gene trap
events. Colonies were counted from 4-OHT treated and
control wells to determine the transposon trapping efﬁ-
ciency and the level of background.
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Excision PCR was performed using a forward and reverse
PCR primer ﬂanking the transposon in the Slingshot
cassette, generating a PCR band of 526bp if the trans-
poson has been mobilized from the donor locus. The
excision PCR was performed at 95 C 15min/ 95 C
0.5min, 62 C 0.5min, 72 C 1.5min: 40 cycles/ 72 C
5min using following primers: FWD: 50-AAGTGTAGC
GGTCACGCTGC-30. REV: 50-CTCGATCACGTTCTG
CTCGT-30.
Drug resistance screen using puromycin and vincristine
To identify genes responsible for puromycin and vincris-
tine resistance, clone PB/PB-1, which carries a single
Slingshot integration, was plated onto 10cm dishes at
10
6 cells per plate. Cells were treat with 1mM 4-OHT
for 2 days before selection in puromycin or vincristine
media commenced. Controls were treated with
95% ethanol as a vehicle control. Selection was performed
with 1mg/ml puromycin or 10pg/ml vincristine for
10 days. Colonies from 4-OHT treated plates were
picked and genomic DNA was extracted to perform
splinkerette PCR for insertion sites isolation.
Splinkerette-PCR and insertion sites analysis
For splinkerette PCR 4mg of genomic DNA was digested
overnight with 20 units of Sau3AI in a 50-ml reaction
volume. After heat inactivation at 65 C for 20min 2.5ml
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Figure 1. Schematic diagram of the Slingshot plasmid and the mutagenesis senarios possible with this system. The Slingshot system was constructed
using a pBluescript II SK(+) vector as backbone (A). The construct can be linearized using the restriction enzyme PacI and stably integrated into a
host cell genome using blastocidin selection. (B) The Slingshot transposon can be mobilized from the stably integrated Slingshot plasmid by treating
cells with 4-OHT which translocates the PB-ERT2 fusion protein to the nucleus and mobilizes the transposon. (C) If the Slingshot transposon
re-integrates downstream of an endogenous promoter ‘X’ it can hijack the promoter resulting in G418 resistance. (D) If the Slingshot transposon
re-integrates upstream of a gene it can overexpress the gene by expression from the CAGGS promoter. (E) It is also possible for the Slingshot
transposon to generate neomorphic alleles such as dominant negative alleles and loss-of-function events by generating intergenic insertions.
(F) Mobilization of the transposon translocates the CAGGS promoter away from the PB-ERT2 preventing further re-mobilization events.
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oligos overnight. This linker ligation served as template
for two rounds of PCR to amplify the transposon/
genome junction. Splinkerette PCR products were
separated by agarose gel electrophoresis, excised from
the gel and sequenced. Primer sequences for splinkerette
PCR and sequencing are provided in Supplementary
Table S1. Sequencing reads were analyzed using
iMapper, an online web tool for insertion site analysis (29).
Western blotting
Cells were lysed in NP-40 lysis buffer with 1mM PMSF.
The protein concentration of each lysate was determined
using the BCA assay (Pierce). Approximately 50mgo f
each lysate was fractionated on an SDS–PAGE gel. The
protein was transferred to Immobilon-P PVDF membrane
(Millipore). The membrane was blocked with 5% milk in
TBST for 1h at room temperature and then incubated
with primary antibodies [anti-Estrogen receptor (ER)
(Santa Cruz Technology) and b-Actin (Cell signaling)]
and then HRP-conjugated secondary antibodies. The
protein bands were visualized using the ECL Western
blotting system (GE Healthcare).
RESULTS AND DISCUSSION
Generation of the Slingshot PB system and Slingshot
ES cell lines
We constructed the Slingshot PB system as shown in
Figure 1. The Slingshot transposon contains a CAGGS
promoter for gain-of-function mutagenesis and elements
for gene trapping to generate loss-of-function mutations
upon integration into the genome. The transposase, driven
by the CAGGS promoter is tamoxifen inducible and has
been described previously (25). After stable integration of
the Slingshot cassette into the genome using blastocidin
selection transposition can be initiated by the administra-
tion of 4-OHT. Mobilization, however, translocates the
CAGGS promoter away from the mPB-L3-ERT2
cDNA, which should eliminate further transposase expres-
sion preventing remobilization. We electroporated 40mg
of linearized Slingshot plasmid into mouse ES cells
(E14Tg2a), selected in blastocidin, and picked 18 stable
integrants for further analysis.
Evaluate the trapping efﬁciency for the Slingshot
transposon
Eighteen ES cell clones carrying the Slingshot plasmid
were plated into six-well plates in duplicate. For each
clone one well was treated with 4-OHT and the other
well was treated with 95% ethanol as a control. As
shown in Figure 2A, 10 of 18 clones showed trapping
activity after 4-OHT treatment. Some clones that were
found to be blastocidin resistant failed to show trapping
activity, which might suggest that the Slingshot PB
plasmid had been damaged during integration, or that
the plasmid had integrated into a site in the genome
where transposon mobilization was not permissive.
Several clones (clones 3, 12, 18) show colony formation
in 4-OHT treated wells but also in control wells suggesting
that the Slingshot plasmid had integrated into a site where
 -geo was promiscuously expressed resulting in G418
resistance. We selected clone 1 (PB/PB-1) for further
analysis because it showed low background and high
inducibility, which was maintained over more than
12 passages (Figure 2B). The Slingshot plasmid integra-
tion sites for this clone were characterized by Southern
blotting, splinkerette PCR and only one donor site was
identiﬁed and mapped on chromosome 18. The excision
of the Slingshot transposon from the PB/PB-1 donor locus
was veriﬁed by excision PCR in eight independent
daughter clones after 4-OHT treatment and G418 selec-
tion (Figure 2C). To assess re-integration events from the
PB/PB-1 Slingshot donor locus we treated PB/PB-1 cells
with 4-OHT, picked 48 G418 resistance clones, and
determined the position of transposon re-integration
events by splinkerette PCR. From the Karyoview
generated by iMapper (29) there did not appear to be
local hopping from the Slingshot donor locus on chromo-
some 18, and insertions appeared to be widely distributed
throughout the genome (Figure 2D).
To further characterize the transposition efﬁciency of
the Slingshot donor in PB/PB-1 cells we performed a
series of mobilization tests to calculate the trapping efﬁ-
ciency following 4-OHT treatment for different time
periods (Supplementary Table S2). From these tests we
obtained trapping efﬁciencies ranging from 0.2 to 0.4%,
with longer 4-OHT treatment resulted in slightly higher
jumping efﬁciency. These experiments suggested that
from a conﬂuent 10cm dish seeded with 10
7 ES cell
there would be sufﬁcient insertion events to generate
over 20000 trapping events covering most permissive
genes in the genome. Although the Slingshot plasmid
uses the mPB-L3-ERT2 transposase which has lower
activity compared with the original PB transposase,
Slingshot transposition is considerably higher when
compared with other studies using plasmid based
delivery methods (21,24,25). It is worth noting in these
experiments that we are equating the trapping efﬁciency
of Slingshot with the mobilization efﬁciency. It is likely
that the mobilization and re-integration efﬁciency of
Slingshot is higher than the systems’ trapping efﬁciency
reported in these experiments.
Drug resistance screens using the Slingshot system
The transposon used in the Slingshot system contains
a CAGGS promoter and splice acceptor—polyA
‘trapping’ elements to generate both gain and loss-of-
function transposition events. The trapping experiments
described earlier essentially validate the loss-of-function
elements of the transposon. Here we set out to test the
gain-of-function capabilities of Slingshot by performing
drug resistances screen in vitro using two agents, the
aminonucleoside antibiotic puromycin and vincristine,
an antimicrotubule spindle poison.
For the puromycin screen two experiments were per-
formed in 10cm plates using 8 and 20 plates seeded with
10
6 PB/PB-1 cells, respectively. From these experiments
44 colonies (18 and 26, respectively) were derived after
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Insertion sites were isolated from these clones
(Figure 3C) by splinkerette PCR and mapped to the
genome with iMapper. Remarkably the insertion sites
were predominantly mapped to two genomic loci. There
were 21 independent insertions that mapped to chromo-
some 5 between 8.5 and 8.8Mb, where the ABC
Transporter genes Abcb1a and Abcb1b are localized
(Figure 3D). Sixteen insertions were located upstream of
Abcb1a. Five insertions were located upstream of Abcb1b
before the ﬁrst exon. Importantly the transposon was
inserted in a sense orientation in this locus such that the
CAGGS promoter will drive overexpression of these
genes. Since the Abcb1a and Abcb1b genes are paralogous,
having evolved as a result of gene duplication, their drug
transporter activity is essentially identical. The other locus
having multiple insertion sites was located on chromo-
some 6 between 58.54 and 58.59 Mb (Figure 3E), where
ﬁve transposon insertion sites were located. These trans-
position events are predicted to drive overexpression of
Abcg2. Abcb1a/b and Abcg2 are ABC drug transporters
and here we show that puromycin is a substrate of both of
these drug pumps (30).
For the screen using vincristine a titration test was per-
formed to establish the optimal concentration of drug for
cell killing (Figure 4). From this test we determined that
drug concentrations between 5.6 and 16.7pg/ml efﬁciently
killed an entire conﬂuent well of a six-well plate within
4days. A dose of 10pg/ml of vincristine was selected for
the screening experiments. Three screens were performed
0
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Figure 2. Slingshot is a potent insertional mutagen. The Slingshot plasmid was introduced into E14Tg2A ES cells and 18 clones were picked. (A).
Mobilization of the Slingshot transposon from the Slingshot plasmid in these lines revealed the background and inducibility of each cell line for gene
trap mutagenesis. (B) Clone one (PB/PB-1) showed high transposition activity and minimal background in gene trap experiments. This activity was
stable of more than 12 passages. (C) Excision PCR on genomic DNA from 8 PB/PB-1 G418 resistant colonies after 4-OHT treatment. Mobilization
of the transposon results in a band of 526bp. The last lane is the PB/PB-1 control DNA without 4-OHT treatment. (D) KaryoView picture generated
by iMapper of the insertion sites isolated from 48 PB/PB-1 G418 resistant clones. The red arrow indicates the original Slingshot transposon
integration site.
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obtained (Figure 4). The insertion sites were cloned by
splinkerette PCR and 11 independent insertions were
mapped to the Abcb1a/b locus on the chromosome 5
between 8.5 and 8.8Mb (Figure 4D). Therefore this
screen has shown that vincristine is a substrate for the
drug transporters Abcb1a/b. In both the puromycin
screen and also in the vincristine screen insertions from
several clones could not be mapped. This was generally
due to the short sequence length of the splinkerette
product or repetitive sequence that could not be mapped
to a single deﬁnitive location on the genome.
Self-inactivation of the Slingshot transposon
after transposition
Transposon remobilization caused by constitutive
transposase expression has the potential to be a major
problem in insertional mutagenesis studies. During trans-
position the Slingshot transposon is excised from a donor
locus and re-integrates elsewhere in the genome
(Figure 1F). In theory this translocates the CAGGS
promoter away from the transposase shutting down
further expression preventing re-mobilization of the trans-
poson. To prove this theory we used puromycin resistant
colonies generated using PB/PB-1 that had integrated
upstream of Abcb1a but were G418 sensitive
(Puro-1-8-14). We treated these cells with 4-OHT and
then selected them in G418 to identify re-mobilization
events, however none were detected illustrating that
transposase activity is completely shutdown following mo-
bilization of the Slingshot transposon (Figure 5A). The
presence of transposon integration events upstream of
Abcb1a was re-conﬁrmed by genomic PCR (data not
shown). Finally to prove that re-mobilization from the
Abcb1a locus is possible we transfected Puro-1, -8, -14
with the mPB-L3-ERT2 plasmid by electroporation,
treated cells with 1mM 4-OHT for 2 days, and then
selected them in G418 (175mg/ml). All three cell lines
treated in this way generated hundreds of colonies per
plate as expected. (Figure 5A). Eight colonies were
picked from mPB-L3-ERT2 transfected 4-OHT treated
Puro-1, -8, -14 cultures and analyzed by PCR to conﬁrm
mobilization of the Slingshot transposon from the Abcb1a
locus (data not shown). While PB-ERT2 expression was
easily detectable in the PB/PB-1 clone using an anti-ER
antibody we were unable to detected PB-ERT2
transposase expression in whole cell lysates from Puro-1,
-8 and -14 clones further conﬁrming that transposition
Plate 1x106cells
+4-OHT (1 µM)
   M-15 Medium
+ Puro (1 µg/ml)
     Pick colonies
1    2   3   4    5   6   7    8   9   10  1„ 2„
Puro-resistant colonies PB/PB-1
5„ Splinkerette PCR for Puro-resistant colonies
AB
C
D
E
2 days
2 days
10 days
Screen Plates
Screened
Colony Formed
+4-OHT - 4-OHT
ScreenI 81 8 2
Screen II 20 26 4
Abcb1a/b Locus
Abcg2 Locus
Figure 3. Puromycin drug resistance screen in the PB/PB-1 Slingshot ES cell line. (A) Overview of the screen. (B) PB/PB-1 ES cells were plated at a
density of 10
6 cells per plate. Two experiments were performed using 8 and 20 plates yielding 18 and 26 puromycin resistant colonies, respectively.
(C) Splinkerette PCR gel picture using 5 prime PCR primers as shown in Supplementary Table S2. Clones 1–8 are puromycin resistant clones isolated
from the screen. 10 and 20 are control DNA from PB/PB-1. The blue arrow indicates a background PCR band (D) Twenty one independent insertion
sites (indicated by blue arrowheads) were mapped to the Abcb1a/b locus on chromosome 5 between 8.5 and 8.8Mb. (E) Five independent insertion
sites (indicated in blue arrowheads) were mapped to the Abcg2 locus on chromosome 6 between 58.54 and 58.59Mb.
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expression (Figure 5B).
The Slingshot transposon system is also active in
somatic cell lines
To expand the utility of the Slingshot system to somatic
cells, in which many cell culture screening systems have
been established, we tested Slingshot in three mammalian
cells lines; the human embryonic kidney cell line 293T and
the Ovarian Carcinoma cell lines OVCAR-3 and PE01. All
three cell lines were transfected with 40mg of linearized
Slingshot plasmid which was introduced into 10
7 cells by
eletroporation (300V, 800mF) and stable integrants were
selected with blastocidin (8mg/ml for 293T, 4mg/ml for
OVCAR-3 and 3mg/ml for PE01). Round monolayer
colonies formed after 2–4weeks of selection. Cells were
treated for 2days with 4-OHT and G418 selection was
carried out for 2–3 weeks at 500mg/ml (293T), 400mg/ml
(OVCAR-3) and 200mg/ml (PE01) to generate data on the
trapping efﬁciency in these cells lines. These human
somatic cell lines showed considerable trapping activity
after 4-OHT treatment (Figure 6). The mobilization of
the Slingshot transposon from the Slingshot plasmid was
conﬁrmed by excision PCR.
CONCLUSIONS
The recent discovery of PB, a transposon derived from the
cabbage looper moth Trichoplusia ni, which is active in
mammalian cells has opened up new opportunities for
insertional mutagenesis (26). Compared to other
insertional mutagens PB has been shown to exhibit
much higher rates of transposition, less local hopping
Plate 1x106 cells
+ 4-OHT (1 µM)
    M-15 Medium
+ Vinc (10 pg/ml)
Pick colonies
AB
C
D
2 days
2 days
10 days
Screen 
ID
Plates
Screened
Colony Formed
+ 4-OHT - 4-OHT
Screen I 30 9 3
Screen II 30 10 2
Screen III 30 8 0
Vincristine (Vinc) drug  titration test for ES cells
1.9 pg/ml 5.6 pg/ml 16.7 pg/ml
Abcb1a/b Locus
Figure 4. Vincristine (Vinc) drug resistance screen in the PB/PB-1 Slingshot ES cell line. (A) Overview of the screen. (B) Titration test for vincristine
in ES cells. (C) Outcome of the drug resistance screen in PB/PB-1 cells using vincristine. (D) Eleven independent insertion sites (indicated in blue
arrowheads) were mapped to the Abcb1a/b locus on chromosome 5 between 8.5 and 8.8 Mb.
Puro-1 Puro-8 Puro-14
PB/PB-1 jumped clones PB/PB-1
Puro-1 Puro-8 Puro-14
+ 4-OHT
+ PB-ERT2
+ 4-OHT
PB-ERT2
b-Actin
A
B
Figure 5. Slingshot is a self-inactivating transposon system. (A) Colony
forming assay to test remobilization in three puromycin resistant
clones, Puro-1, -8, -14. These three clones are derived from PB/PB-1
and all contain a PB transposon copy inserted upstream of the ABC
transporter gene Abcb1a but are G418 sensitive. While there was no
transposition after 4-OHT treatment of Puro-1, -8, -14 (top plates)
transfection of a PB-ERT2 plasmid into these cell lines followed by
4-OHT treatment reveals that the Slingshot transposon can be
remobilized from the Abcb1a locus (bottom plates) (B) Western Blot
for PB-ERT2 transposase expression using an anti-ER antibody.
Expression of PB-ERT2 is readily detectable in the PB/PB-1 control
cells but completely absent from Puro-1, -8, -14.
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transposase can be fused to other sequences which has
made it possible to control transposition temporally
(21,24,26,28). Here we have developed a system called
Slingshot, which can be used for self-inactivating
insertional mutagenesis in mouse ES cells and also in a
range of human somatic cell lines. We show that Slingshot
can be used for genome-wide mutagenesis by performing
two screens to identify mediators of resistance to the com-
pounds puromycin and vincristine. Slingshot has several
potential applications. First, as we have shown here,
Slingshot represents a useful tool for genome-wide
screens, secondly since the transposon is mobilized from
a stable chromosomal donor by adding the ligand tamoxi-
fen to the medium Slingshot can be used in heterogeneous
populations of cells, in three dimensional culture systems,
or where it is impractical to transiently transfect donor
and helper plasmids into cells, and in cell lines that are
hard to transfect. Thirdly, since the transposon is
mobilized once and only once following the administra-
tion of tamoxifen the Slingshot system can be used to
‘barcode’ populations of cells making it possible to track
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Figure 6. Slingshot is functional in a range of human somatic cell lines. Trapping efﬁciency assays and excision PCRs were performed in HEK293,
OVCAR3 and PE01 cells stably transfected with the Slingshot plasmid. The Slingshot transposon could be mobilized in HEK293 (A–C), OVCAR3
(D–F) and also in PE01 (G–I) cells following 4-OHT administration resulting in gene trap events following analysis of 19, 18 and 11 clones from
these cell lines, respectively. Excision PCR was performed in clones from each cell line pre- and post- 4-OHT treatments. N.C., negative control;
P.C., positive control (DNA from the Puro-1 cell line or a mobilized human control). Human GAPDH was used as a gDNA loading control.
(J) Western blot analysis of expression of the fusion protein PB-ERT2 in a highly active PB-carrying OVCAR3 clone following serial passage. The
fusion protein was detected using an antibody recognizing the ERT2 domain. Parental OVCAR3 cells were used as a negative control. b-Actin was
used as a loading control.
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When combined with high-throughput sequencing to
read the insertion sites from a population of cells, like a
molecular barcode, it should be possible to use Slingshot
in synthetic genetic screens, such as those performed in
yeast, opening up new opportunities for cell fate studies.
We are in the process of further developing the Slingshot
system so that it can be targeted into the Rosa locus, and
also introduced into cells in culture in a lentivirus to fa-
cilitate the generation of single copy integrants.
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